CSC populations expressing CD133+ cells in multiple cancers, including glioblastoma, non-small cell lung cancer and colon cancer, presented worse 5-year overall survival and higher rates of chemotherapy and radiation resistance than the CD133-negative cells [49,51,52]. This evidence concerns the gene PROM1 and glioblastoma.